These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 25654736)

  • 21. Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer.
    Chedgy EC; Douglas J; Wright JL; Seiler R; van Rhijn BW; Boormans J; Todenhöfer T; Dinney CP; Collins CC; Van der Heijden MS; Black PC
    Urol Oncol; 2016 Oct; 34(10):469-76. PubMed ID: 27317490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A precision, personalized approach to the management of bladder cancer.
    Apolo AB; Burger M
    Curr Opin Urol; 2015 Sep; 25(5):416-7. PubMed ID: 26153639
    [No Abstract]   [Full Text] [Related]  

  • 23. Clostridium perfringens enterotoxin as a potential drug for intravesical treatment of bladder cancer.
    Gabig TG; Waltzer WC; Whyard T; Romanov V
    Biochem Biophys Res Commun; 2016 Sep; 478(2):887-92. PubMed ID: 27520378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Update on FGFR3 mutation and multiple regional epigenetic silencing (MRES) phenotype in urothelial carcinogenesis].
    Masson-Lecomte A; Vordos D; de la Taille A; Neuzillet Y; Radvanyi F; Allory Y
    Prog Urol; 2013 Feb; 23(2):96-8. PubMed ID: 23352301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?
    Garczyk S; Schneider U; Lurje I; Becker K; Vögeli TA; Gaisa NT; Knüchel R
    PLoS One; 2018; 13(8):e0202965. PubMed ID: 30138427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer.
    Pal SK; Agarwal N; Boorjian SA; Hahn NM; Siefker-Radtke AO; Clark PE; Plimack ER
    J Clin Oncol; 2016 Sep; 34(27):3346-8. PubMed ID: 27458279
    [No Abstract]   [Full Text] [Related]  

  • 27. Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.
    Wei L; Chintala S; Ciamporcero E; Ramakrishnan S; Elbanna M; Wang J; Hu Q; Glenn ST; Murakami M; Liu L; Gomez EC; Sun Y; Conroy J; Miles KM; Malathi K; Ramaiah S; Anbarasu A; Woloszynska-Read A; Johnson CS; Conroy J; Liu S; Morrison CD; Pili R
    Oncotarget; 2016 Nov; 7(47):76374-76389. PubMed ID: 27823983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New directions for biologic targets in urothelial carcinoma.
    Richter S; Sridhar SS
    Mol Cancer Ther; 2012 Jun; 11(6):1226-35. PubMed ID: 22572812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New insights into the influence of cigarette smoking on urothelial carcinogenesis: smoking-induced gene expression in tumor-free urothelium might discriminate muscle-invasive from nonmuscle-invasive urothelial bladder cancer.
    Gabriel U; Li L; Bolenz C; Steidler A; Kränzlin B; Saile M; Gretz N; Trojan L; Michel MS
    Mol Carcinog; 2012 Nov; 51(11):907-15. PubMed ID: 21976419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
    Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A
    Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urothelial neoplasms of the urinary bladder occurring in young adult and pediatric patients: a comprehensive review of literature with implications for patient management.
    Paner GP; Zehnder P; Amin AM; Husain AN; Desai MM
    Adv Anat Pathol; 2011 Jan; 18(1):79-89. PubMed ID: 21169741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer.
    Otto W; Denzinger S; Bertz S; Gaumann A; Wild PJ; Hartmann A; Stoehr R
    Int J Cancer; 2009 Nov; 125(9):2205-8. PubMed ID: 19621447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic and therapeutic applications of the molecular events in clinical management of urothelial carcinoma of bladder.
    Garg M
    J Exp Ther Oncol; 2014; 10(4):301-16. PubMed ID: 25509986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted therapies in urothelial bladder cancer: a disappointing past preceding a bright future?
    Hindy JR; Souaid T; Kourie HR; Kattan J
    Future Oncol; 2019 May; 15(13):1505-1524. PubMed ID: 30977669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deciphering the Molecular Mechanism Underlying the Inhibitory Efficacy of Taiwanese Local Pomegranate Peels against Urinary Bladder Urothelial Carcinoma.
    Chang CP; Chan YY; Li CF; Chien LH; Lee ST; Wu TF
    Nutrients; 2018 Apr; 10(5):. PubMed ID: 29702555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Urothelial carcinoma of the bladder in patients aged 30 years or younger: clinicopathological analysis and expression of fibroblast growth factor receptor 3 (FGFR3) of 45 cases.
    Huang H; Sun M; Li X; Jin J
    Med Oncol; 2015 May; 32(5):137. PubMed ID: 25801230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The evolution of bladder cancer genomics: What have we learned and how can we use it?
    Audenet F; Attalla K; Sfakianos JP
    Urol Oncol; 2018 Jul; 36(7):313-320. PubMed ID: 29573965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors.
    Knowles MA
    Future Oncol; 2008 Feb; 4(1):71-83. PubMed ID: 18241002
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human Epidermal Growth Factor Receptor 2 Overexpression in Micropapillary and Other Variants of Urothelial Carcinoma.
    Behzatoğlu K; Yörükoğlu K; Demir H; Bal N
    Eur Urol Focus; 2018 Apr; 4(3):399-404. PubMed ID: 28753766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
    Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
    Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.